Clinical Trial Update: Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors [Phase 2, Phase 3]

View source ↗

Summary

ClinicalTrials.gov shows a phase 2/3 trial of cannabidiol in COVID-19 patients with cardiovascular disease or risk factors was terminated. The results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Cardiol Therapeutics Inc. | Conditions: COVID-19, Cardiovascular Diseases | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-07-25